Healthcare Analyst Blum, along with Dr. David Lieberman, a pediatric neurologist and faculty member at Boston Children’s Hospital, discuss Taysha Gene Therapies (TSHA) 102’s recent clinical/regulatory update in Rett Syndrome, in conjunction with this year’s IRSF Meeting, on an Analyst/Industry conference call to be held on June 9 at 12 pm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies price target raised to $8 from $6 at Needham
- Positive Outlook for Taysha Gene Therapies: Buy Rating on Promising TSHA-102 Advancements
- Positive Outlook for Taysha Gene Therapies: Strong Study Design and Promising Data Support Buy Rating
- Taysha Gene Therapies Announces Major Stock Offering
- Taysha Gene Therapies price target raised to $9 from $7 at Chardan